Pressemitteilungen zu dem Thema colitis


Unterkategorien

PresseMitteilungen zu dem Schlagwort colitis


Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

LOS ANGELES, CA -- (Marketwired) -- 10/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced additional positive preclinical efficacy results for the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, wh ...


19.10.2017

Asana Medical, Inc. to Present as Innovation Challenge Finalist at RESI Boston Conference 2017

MIAMI LAKES, FL -- (Marketwired) -- 09/11/17 -- ., ("Asana," the "Company"), a regenerative medicine company developing a novel treatment for Ulcerative Colitis, is pleased to announce that it has been selected as an Innovation Challenge Finalist and will present at the in Boston, Massachusetts on Tuesday, September 26th, 2017. The RESI (Redefining Early Stage Investments) Conference is an investor conference for early-stage life science companies, and is being held at the ...


11.09.2017

Dr. Susan G. Manella Joins Asana''s Medical Advisory Board

MIAMI LAKES, FL -- (Marketwired) -- 08/24/17 -- ., ("Asana," the "Company"), a regenerative medicine company that is developing a novel treatment for Inflammatory Bowel Disease ("IBD"), including Ulcerative Colitis and Crohn''s Disease, is pleased to announce that Dr. Susan G. Manella has accepted the Company''s offer to join its Medical Advisory Board. Dr. Manella will assume the board''s leadership role in managing information flow a ...


24.08.2017

Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, know ...


19.07.2017

Vitality Biopharma Releases Clinical Report of Cannabinoid Therapy for Pediatric IBD

LOS ANGELES, CA -- (Marketwired) -- 04/20/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the release of one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory ...


20.04.2017

Pharmaceutical Industry Executive Brian W. Andersen Named Chief Business Officer at Asana Medical, Inc.

MIAMI LAKES, FL -- (Marketwired) -- 04/18/17 -- ., ("Asana," the "Company"), a regenerative medicine company that is developing a novel treatment for Inflammatory Bowel Disease ("IBD"), including Ulcerative Colitis and Crohn''s Disease, is pleased to announce that Brian W. Andersen, an experienced industry executive with a proven record of commercial excellence, has been appointed as its Chief Business Officer.Mr. Andersen brings to Asana an impressive tr ...


18.04.2017

Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis

DUBLIN, IRELAND -- (Marketwired) -- 10/04/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 1b clinical trial of TD-1473 in patients with moderate to severe ulcerative colitis. TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases. ...


04.10.2016

Asana Medical, Inc.''s Preclinical Study Indicates Promising Solution to Treat Ulcerative Colitis

MIAMI LAKES, FL -- (Marketwired) -- 10/04/16 -- . ("Asana," the "Company"), a regenerative medicine company focused on development and commercialization of its innovative xtraellular atrix ydrogel ("ECMH") technology for the treatment of Inflammatory Bowel Disease ("IBD"), today announced significant positive results from preclinical research conducted in collaboration with the research team of Dr. Stephen Badylak D.V.M., Ph.D., M.D. at the University of ...


04.10.2016

Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO"

LOS ANGELES, CA -- (Marketwired) -- 08/17/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that effective immediately, its common stock now trades on the over-the-counter market under the symbol "VBIO."Trading of the company''s stock und ...


17.08.2016

Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/27/16 -- (OTCQB: STVFD) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced updates to its clinical development plans including the advancement of cannabosides for the treatment of inflammatory bowel disease.Vitality Biopharma has developed a new cl ...


27.07.2016

Feast of Saint Arnold Raises $106,000 for Texas Children''s Hospital

HOUSTON, TX -- (Marketwired) -- 07/21/16 -- Saint Arnold Brewing Co. (), the oldest craft brewery in Texas, today announced the 2016 Feast of Saint Arnold raised a total of $106,000 for Texas Children''s Hospital Inflammatory Bowel Disease (IBD) Center. The funds will support research into IBD, a group of autoimmune disorders including Crohn''s Disease and ulcerative colitis, which together affect approximately 1.6 million Americans. A portion of funds also cover the costs o ...


21.07.2016

Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

DUBLIN, IRELAND -- (Marketwired) -- 06/09/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced positive results from the Company''s Phase 1 clinical trial of TD-1473, a novel, potent, and orally administered GI-targeted pan-Janus kinase (JAK) inhibitor. TD-1473 is specifically designed to penetrate the intestinal wall and act directly at the site of inflammation with minimal systemic exposure.Data from the study ...


09.06.2016

Asana Medical, Inc. CEO Dr. Christine V. Sapan to Present at 2016 BIO International Convention June 8th

MIAMI LAKES, FL -- (Marketwired) -- 06/01/16 -- ., ("Asana," the "Company"), an emerging life science company focused on the development and commercialization of its innovative tissue engineered therapy to treat Inflammatory Bowel Disease ("IBD"), is pleased to announce that CEO Dr. Christine V. Sapan will be presenting at the , being held this year at the Moscone Center in San Francisco, CA from June 6th through June 9th. Dr. Sapan is scheduled to present at the S ...


01.06.2016

Asana Medical, Inc. Adds Dr. Hal K. Wrigley to Board of Directors

MIAMI LAKES, FL -- (Marketwired) -- 05/18/16 -- ., ("Asana," the "Company"), an emerging life science company focused on the development and commercialization of its innovative tissue engineered therapy to treat Inflammatory Bowel Disease ("IBD"), is pleased to announce that Dr. Hal Wrigley has joined the Company''s Board of Directors.Dr. Wrigley, a dentist by trade and entrepreneur, graduated from The University of Pittsburgh, where he earned a Bachelor& ...


18.05.2016

Asana Medical, Inc. Announces Closing of $1.2 Million Convertible Promissory Note Offering

MIAMI LAKES, FL -- (Marketwired) -- 05/10/16 -- . ("Asana," the "Company") is pleased to announce that it has closed a $1.2 million offering of convertible promissory notes. Asana, an emerging life sciences company, is focused on the development and commercialization of an innovative therapy to non-surgically treat Inflammatory Bowel Diseases ("IBD"), including Ulcerative Colitis ("UC"), Crohn''s Disease and Rectal Mucositis.Asana''s l ...


10.05.2016

Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI) for Ulcerative Colitis

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/06/16 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune response, announced it has been awarded funding of $240,000 from Genome British Columbia (Genome BC) to support a Phase 2a clinical trial of Qu Biologics'' QBECO SSI for the treatment of moderate-to-severe ulcerative colitis (UC).In this study, Qu Biologics will investigate the safety, efficacy a ...


06.04.2016

Asana Medical, Inc. Names Dr. Christine V. Sapan CEO, Adds University of Miami''s Sergio M. Gonzalez to Its Board of Directors

MIAMI LAKES, FL -- (Marketwired) -- 03/02/16 -- ., ("Asana," the "Company"), an emerging life science company focused on the development and commercialization of its innovative tissue engineered therapy to treat Inflammatory Bowel Disease ("IBD"), is pleased to announce that Dr. Christine V. Sapan has been named Chief Executive Officer of Asana Medical, Inc. Dr. Sapan, previously Asana''s , will continue guiding the Company in the development of its first ...


02.03.2016

Qu Biologics Closes Oversubscribed Financing; Crohn''s Disease Phase 2 Clinical Trial Results in First Quarter 2016

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 12/23/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune response, announced it has closed an oversubscribed private financing of CDN$3.5 million bringing the total private equity capital raised to CDN$19 million to date.Dr. Hal Gunn, CEO of Qu Biologics commented, "We are pleased with the high level of interest from private equity investors who clearly sha ...


23.12.2015

Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

DUBLIN, IRELAND -- (Marketwired) -- 12/10/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-1473, a novel, potent, and orally administered GI-targeted pan-Janus kinase (JAK) inhibitor. The Company is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases.TD-1473 is an internally-discovered JAK ...


10.12.2015

Dr. Christine V. Sapan Named President of Asana Medical, Inc.

MIAMI LAKES, FL -- (Marketwired) -- 11/09/15 -- Asana Medical, Inc., ("Asana," the "Company"), an emerging life science company focused on the development and commercialization of its innovative tissue engineered therapy to treat Inflammatory Bowel Disease ("IBD"), is pleased to announce that Dr. Christine V. Sapan has been named President of Asana Medical, Inc. Dr. Sapan will assume the role and responsibilities of Marc Ramer, Founder and former CEO. Dr. Sapan wil ...


09.11.2015

Asana Medical''s Treatment of IBD Progresses With Execution of Research Agreement With University of Pittsburgh

MIAMI LAKES, FL -- (Marketwired) -- 09/09/15 -- Asana Medical, Inc., ("Asana," the "Company"), an emerging life science company focused on the development and commercialization of its innovative engineered tissue therapy to treat Inflammatory Bowel Disease ("IBD"), has executed a Corporate Research Agreement ("CRA") with the University of Pittsburgh to develop products based on intellectual property recently licensed from the University. Under the CRA, As ...


09.09.2015

Qu Biologics Begins Phase 2 Clinical Trial in Ulcerative Colitis

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/28/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has initiated a .Qu Biologics'' clinical trial in ulcerative colitis has been initiated at the GI Research Institute in Vancouver, the first of at least four clinical trial sites in Canada. In the coming weeks, three additional sites will open in Edmonton, Calgary and ...


28.07.2015

Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target

SAN FRANCISCO, CA -- (Marketwired) -- 07/23/15 -- announced today that it has initiated coverage on (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. (''IMNP''), headquartered in New York, is a clinical stage biopharmaceutical company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients w ...


23.07.2015

Qu Biologics Begins Research Collaboration with Dr. Bruce Vallance at the University of British Columbia to Study SSI Treatment for Inflammatory Bowel Disease

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/14/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today it has begun a research collaboration with the laboratory of .Dr. Vallance''s team will be studying the therapeutic effects of Qu Biologics'' SSI treatment for inflammatory bowel disease (Crohn''s disease and ulcerative colitis) in a mouse mo ...


14.07.2015

StockNewsNow.com Publishes New SNNLive Video Interview With Immune Pharmaceuticals, Inc.

LOS ANGELES, CA -- (Marketwired) -- 06/25/15 -- , The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), applies a personalized, bio-marker based approach to treating inflammatory diseases and cancer through the development of novel, targeted, monoclonal antibody therapeutics, according to the company''s website (see here: ). The video interview was recorded at the Marcum MicroCap Confer ...


25.06.2015

Asana Medical, Inc. Secures Core Technology License for Treatment of IBD Including Ulcerative Colitis

MIAMI LAKES, FL -- (Marketwired) -- 06/03/15 -- ., ("Asana," the "Company"), an emerging medical device company focused on the development and commercialization of its innovative engineered tissue therapy to treat Inflammatory Bowel Disease ("IBD"), has obtained a world-wide, field specific, exclusive license from the University of Pittsburgh on multiple patents and patent applications covering methods and for treating Inflammatory Bowel Disease without a colectomy ...


03.06.2015

Asana Medical, Inc. to Present at 2015 BIO International Convention June 15th - 18th

MIAMI LAKES, FL -- (Marketwired) -- 06/01/15 -- . ("Asana," the "Company"), an emerging medical device company focused on the development and commercialization of its innovative tissue-engineered therapy to treat Inflammatory Bowel Disease ("IBD"), is pleased to announce that it will be participating as an exhibitor and presenter at the being held in Philadelphia, PA. June 15th - 18th."We are looking forward to attending the BIO International Convention and t ...


01.06.2015

Innovate Biopharmaceuticals Acquires Late-Stage Pancreatic Imaging Assets

RALEIGH, NC -- (Marketwired) -- 01/05/15 -- ("Innovate") has entered into an agreement to purchase all assets related to RG-1068, a synthetic version of human secretin from . Repligen has completed a Phase 3 study demonstrating that RG-1068 improved detection of pancreatic duct abnormalities in patients with known or suspected pancreatitis. The acquisition includes a New Drug Application (NDA) filed for RG-1068 with the U.S Food and Drug Administration (FDA), a Marketing Authorizatio ...


05.01.2015

DGAP-News: Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis

Synergy Pharmaceuticals 28.01.2013 11:00 --------------------------------------------------------------------------- SP-333 Advances to Multiple-Dosing Safety Study NEW YORK, 2013-01-28 11:00 CET (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today that oral dosing of healthy volunteers has begun in a Phase I clinical trial of SP-333, a guanylate cyclase C (GC-C) agonist for the treatment of inflam ...


28.01.2013

DGAP-News: Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

Synergy Pharmaceuticals 14.12.2012 14:00 --------------------------------------------------------------------------- Scientific Poster Presentation at 2012 Advances in IBD Conference NEW YORK, 2012-12-14 14:00 CET (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that a poster presentation on SP-333, Synergy's next-generation guanylate cyclase-C (GC-C) agonist to treat ulcerative col ...


14.12.2012

DGAP-News: Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans

Synergy Pharmaceuticals 22.10.2012 23:00 --------------------------------------------------------------------------- Scientific Poster Presentation This Week at ACG 2012 NEW YORK, 2012-10-22 23:00 CEST (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced a presentation on SP-333, the company's second investigational drug from the guanylate cyclase-C agonist class, at the American Colleg ...


22.10.2012

DGAP-News: Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis

Synergy Pharmaceuticals 22.10.2012 12:00 --------------------------------------------------------------------------- NEW YORK, 2012-10-22 12:00 CEST (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that on October 19, 2012 the company initiated oral dosing of healthy adult volunteers in a Phase I clinical trial of SP-333, a guanylate cyclase C (GC-C) agonist designed to treat ulcerative colitis (UC). ...


22.10.2012



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 101


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.